<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691700</url>
  </required_header>
  <id_info>
    <org_study_id>Y0075</org_study_id>
    <secondary_id>jRCT</secondary_id>
    <nct_id>NCT04691700</nct_id>
  </id_info>
  <brief_title>GOREISAN for Heart Failure (GOREISAN-HF) Trial</brief_title>
  <acronym>GOREISAN-HF</acronym>
  <official_title>GOREISAN for Heart Failure (GOREISAN-HF) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeshi Morimoto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the GOREISAN-HF trial is to assess the effect of the administration of&#xD;
      Goreisan (TJ-17) plus standard therapy compared to standard therapy alone on the improvement&#xD;
      rate of cardiac edema and clinical outcomes in worsening congestive heart failure with volume&#xD;
      overload.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current guidelines recommend the use of loop diuretics as an indication for class I to&#xD;
      improve HF symptoms regardless of left ventricular ejection fraction. Loop diuretics,&#xD;
      however, are known to activate the renin-angiotensin-aldosterone system and the sympathetic&#xD;
      nervous system, which could accelerate HF progression. Loop diuretics could also cause&#xD;
      worsening renal function and electrolyte disturbance, and it is desirable to have an&#xD;
      alternative drug to loop diuretics to effectively relieve congestive symptoms. Goreisan&#xD;
      (TJ-17), a traditional Japanese medicine composed of five herbal medicines, has long been&#xD;
      used in Japan to treat impairments of the regulation of body fluid homeostasis, including&#xD;
      edema, and has been less likely to cause renal dysfunction and electrolyte abnormalities. We&#xD;
      therefore planned a multicenter, randomized, interventional, parallel assignment, open-label&#xD;
      treatment trial to evaluate the long-term effect of in-hospital initiation of Goreisan, when&#xD;
      added to standard therapy, in patients with worsening congestive heart failure and clear&#xD;
      signs of volume overload.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of cardiac edema</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiac edema is defined as conditions having one or more following conditions: lower limb edema, pleural effusion, or pulmonary congestion on chest x-ray. Lower limb edema, pleural effusion, and pulmonary congestion are assessed by investigators. Improvement is defined as the disappearance of all signs of cardiac edema.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite endpoint of all-cause death or hospitalization</measure>
    <time_frame>3 years</time_frame>
    <description>Composite of death from any cause or hospitalization from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score</measure>
    <time_frame>6 months</time_frame>
    <description>The KCCQ is a validated self-administered instrument of quality of life and health status in heart failure (HF) patients. The clinical summary score is a composite assessment of physical limitation, total symptom score, health-related quality of life, and social limitation scores. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in loop diuretics dose</measure>
    <time_frame>6 months</time_frame>
    <description>Loop diuretic dose will be calculated as furosemide-equivalent dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in loop diuretics dose</measure>
    <time_frame>1 year</time_frame>
    <description>Loop diuretic dose will be calculated as furosemide-equivalent dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of sustained decline in eGFR ≥50%, ESRD (end stage renal disease) or renal death</measure>
    <time_frame>3 years</time_frame>
    <description>End Stage Renal Disease (ESRD) is defined as: Sustained eGFR &lt;15 mL/min/1.73m2, Chronic dialysis treatment or, receiving a renal transplant. Renal death is defined as renal failure as the underlying cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug event</measure>
    <time_frame>3 years</time_frame>
    <description>Adverse drug event is an injury resulting from medical intervention related to any drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a composite congestion score</measure>
    <time_frame>1 month</time_frame>
    <description>Dyspnea, fatigue, orthopnea, jugular vein distention, rales, plueral effusion, and lower limb edema are assessed on a standardized 4-point scale ranging from 0 to 3. A composite congestion score is calculated by summing the individual scores for dyspnea, fatigue, orthopnea, jugular vein distention, rales, plueral effusion, and lower limb edema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a composite congestion score</measure>
    <time_frame>6 months</time_frame>
    <description>Dyspnea, fatigue, orthopnea, jugular vein distention, rales, plueral effusion, and lower limb edema are assessed on a standardized 4-point scale ranging from 0 to 3. A composite congestion score is calculated by summing the individual scores for dyspnea, fatigue, orthopnea, jugular vein distention, rales, plueral effusion, and lower limb edema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a composite congestion score</measure>
    <time_frame>1 year</time_frame>
    <description>Dyspnea, fatigue, orthopnea, jugular vein distention, rales, plueral effusion, and lower limb edema are assessed on a standardized 4-point scale ranging from 0 to 3. A composite congestion score is calculated by summing the individual scores for dyspnea, fatigue, orthopnea, jugular vein distention, rales, plueral effusion, and lower limb edema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause hospitalization</measure>
    <time_frame>3 years</time_frame>
    <description>Hospitalization from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of all-cause death or hospitalization for heart failure</measure>
    <time_frame>3 years</time_frame>
    <description>Composite of death from any cause or hospitalization for heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>3 years</time_frame>
    <description>Hospitalization for heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>3 years</time_frame>
    <description>Death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiovascular death</measure>
    <time_frame>3 years</time_frame>
    <description>Death other than death from cardiac or vascular diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association (NYHA) functional class</measure>
    <time_frame>6 months</time_frame>
    <description>Change in New York Heart Association (NYHA) functional class, a well established grading scale to classify a patients' level of functionality based on the signs and symptoms of patient with heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-terminal pro brain-type natriuretic peptide (NT-proBNP)</measure>
    <time_frame>1 month</time_frame>
    <description>Change in N-terminal pro brain-type natriuretic peptide (NT-proBNP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-terminal pro brain-type natriuretic peptide (NT-proBNP)</measure>
    <time_frame>6 month</time_frame>
    <description>Change in N-terminal pro brain-type natriuretic peptide (NT-proBNP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-terminal pro brain-type natriuretic peptide (NT-proBNP)</measure>
    <time_frame>1 year</time_frame>
    <description>Change in N-terminal pro brain-type natriuretic peptide (NT-proBNP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct healthcare cost</measure>
    <time_frame>1 year</time_frame>
    <description>Direct healthcare cost (Japanese Yen) from the time of randomization to 12 months was obained from the claim data patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2192</enrollment>
  <condition>Heart Failure</condition>
  <condition>Edema</condition>
  <condition>Traditional Japanese Medicine</condition>
  <condition>Kampo Medicine</condition>
  <condition>Clinical Trial</condition>
  <arm_group>
    <arm_group_label>Goreisan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Goreisan (TJ-17) will be added at a dose of 7.5g per day to standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Goreisan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment without Goreisan (TJ-17)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goreisan</intervention_name>
    <description>Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics</description>
    <arm_group_label>Goreisan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Treatment</intervention_name>
    <description>Standard therapy without Goreisan</description>
    <arm_group_label>No Goreisan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed congestive heart failure (CHF) by Framingham criteria&#xD;
&#xD;
          -  CHF patients with cardiac edema and signs due to cardiac edema (signs of fluid&#xD;
             overload: lower limb edema, pulmonary effusion, or pulmonary congestion on chest&#xD;
             x-ray)&#xD;
&#xD;
          -  Elevated N-terminal pro brain-type natriuretic peptide (NT-proBNP) ≥300 pg/mL or brain&#xD;
             natriuretic peptide (BNP) ≥100 pg/mL at enrollment&#xD;
&#xD;
          -  Patients ≥ 20 years of age, male or female&#xD;
&#xD;
          -  Provision of signed informed consent before any assessment is performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo&#xD;
             any of these operations after randomization&#xD;
&#xD;
          -  Implantation of a cardiac resynchronization therapy (CRT) within 12 weeks prior to&#xD;
             enrollment or intent to implant a CRT device&#xD;
&#xD;
          -  Previous cardiac transplantation or implantation of a ventricular assistance device or&#xD;
             similar device, or implantation expected after randomization&#xD;
&#xD;
          -  End-stage renal failure (estimated glomerular filtration rate [eGFR] &lt;15&#xD;
             mL/min/1.73m2) at enrollment&#xD;
&#xD;
          -  Patients who are expected to have a life expectancy of 6 months or less&#xD;
&#xD;
          -  Acute coronary syndrome at screening&#xD;
&#xD;
          -  Women of child-bearing potential or women who have a positive pregnancy test at&#xD;
             enrolment or randomization&#xD;
&#xD;
          -  Treatment with herbal medicine at enrollment&#xD;
&#xD;
          -  Confirmed poor tolerability of Goreisan (including cinnamon allergy)&#xD;
&#xD;
          -  Considered not appropriate for the participation of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Kimura, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeshi Kimura, MD, PhD</last_name>
    <phone>+81-75-751-4254</phone>
    <email>taketaka@kuhp.kyoto-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hidenori Yaku, MD, PhD</last_name>
    <phone>+81-75-751-4255</phone>
    <email>yakuh@kuhp.kyoto-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kyoto University Graduate School of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takeshi Kimura, MD, PhD</last_name>
      <phone>+81-75-751-4254</phone>
      <email>taketaka@kuhp.kyoto-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takeshi Kimura, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Takeshi Morimoto</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Edema</keyword>
  <keyword>Traditional Japanese Medicine</keyword>
  <keyword>Goreisan (TJ-17)</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

